Matrix Cell Research Institute Inc. of Ushiku City, Ibaraki at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manufacturers

Matrix Cell Research Institute Inc.

1-35-3 Kamikashiwada, 300-1232 Ushiku City, Ibaraki
Japan
Telephone +81 3 5822 1781
Fax +81 3 5822 1783
takumi@mag-sense.com

This company is co-exhibitor of
Japan Agency for Medical Research and Development

Hall map

MEDICA 2019 hall map (Hall 15): stand H16

Fairground map

MEDICA 2019 fairground map: Hall 15

Contact

Moriaki Kusakabe

Our range of products

Product categories

  • 01  Electromedical Equipment / Medical Technology
  • 01.03  Surgery devices, endoscopy devices
  • 01.03.02  Instruments for the minimal-invasive surgery (MIS)

Instruments for the minimal-invasive surgery (MIS)

Our products

Product category: Instruments for the minimal-invasive surgery (MIS)

TAKUMI Magnetic Probe

Handheld magnetic probe for sentinel lymph node identification.

Our magnetic sensing technology solves the limitations of the radioisotope technique for SLN detection, which can greatly improve quality of life for breast cancer patients.

More Less

Company news

Date

Topic

Download

Jul 1, 2019

Matrix Cell Research Institute Inc. Acquires CE Marking for TAKUMI

Matrix Cell Research Institute Inc. has – effective as of July 1, 2019 – acquired CE Marking (Notified Body Number: 0344) for TAKUMI in the European Union. Approval of CE Marking means that TAKUMI, the handheld magnetic probe for detection of magnetic fluid used to identify cancer metastases in Sentinel Lymph Nodes, conforms to requirements for sale in the European economic area.
In accordance with Directive 93/42/EEC on Medical devices, Annex V, the CE Marking of Conformity guarantees that TAKUMI fulfils the highest level of safety for patients and users alike.

More Less

About us

Company details

Matrix Cell Research Institute Inc. was established in 2005.

The companies main focus is providing small- to medium-scale hospitals and medical facilities with solutions to improve cancer patients’ opportunities for early treatment and overall quality of life.

More Less

Company data

Number of employees

1-19